Please ensure Javascript is enabled for purposes of website accessibility

Poll: Katie Porter Holds Early Edge in California Governor’s Race

37 minutes ago

Just 38% of Americans Support Trump’s Use of Troops to Police DC, Reuters/Ipsos Poll Finds

2 hours ago

Families Leave Gaza City After Night of Bombardment, Israelis Protest

4 hours ago

California Farming Couple Seeks $300 Million for Aspen Estate

5 hours ago

Trump Administration Cannot Sue Maryland Federal Judges Over Immigration Order, Judge Rules

5 hours ago

California Republicans Sue to Block Congressional Redistricting Plan

21 hours ago

Trump To Sign Executive Order Directing AG To Prosecute Flag Desecration

1 day ago

Fresno County DUI Crash Sends Car Into Embankment Near Highway 99

1 day ago
Moderna Asking Regulators to OK Its Virus Shots
gvw_ap_news
By Associated Press
Published 5 years ago on
November 30, 2020

Share

Moderna Inc. said it would ask U.S. and European regulators Monday to allow emergency use of its COVID-19 vaccine as new study results confirm the shots offer strong protection — ramping up the race to begin limited vaccinations as the coronavirus rampage worsens.

Multiple vaccine candidates must succeed for the world to stamp out the pandemic, which has been on the upswing in the U.S. and Europe. U.S. hospitals have been stretched to the limit as the nation has seen more than 160,000 new cases per day and more than 1,400 daily deaths. Since first emerging nearly a year ago in China, the virus has killed more than 1.4 million people worldwide.

Moderna is just behind Pfizer and its German partner BioNTech in seeking to begin vaccinations in the U.S. in December. British regulators also are assessing the Pfizer shot and another from AstraZeneca.

Moderna created its shots with the U.S. National Institutes of Health and already had a hint they were working, but said it got the final needed results over the weekend that suggest the vaccine is more than 94% effective.

Of 196 COVID-19 cases so far in its huge U.S. study, 185 were trial participants who received the placebo and 11 who got the real vaccine. The only people who got severely ill — 30 participants, including one who died — had received dummy shots, said Dr. Tal Zaks, the Cambridge, Massachusetts, company’s chief medical officer.

When he learned the results, “I allowed myself to cry for the first time,” Zaks told The Associated Press. “We have already, just in the trial, have already saved lives. Just imagine the impact then multiplied to the people who can get this vaccine.”

Moderna said the shots’ effectiveness and a good safety record so far — with only temporary, flu-like side effects — mean they meet requirements set by the U.S. Food and Drug Administration for emergency use before the final-stage testing is complete. The European Medicines Agency, Europe’s version of FDA, has signaled it also is open to faster “conditional” clearance.

What Comes Next

The FDA has pledged that before it decides to roll out any COVID-19 vaccines, its scientific advisers will publicly debate whether there’s enough evidence behind each candidate.

First up on Dec. 10, Pfizer and BioNTech will present data suggesting their vaccine candidate is 95% effective. Moderna said its turn at this “science court” is expected exactly a week later, on Dec. 17.

Rationing Initial Doses

If the FDA allows emergency use, Moderna expects to have 20 million doses ready for the U.S. by year’s end. Recipients will need two doses, so that’s enough for 10 million people.

Pfizer expects to have 50 million doses globally in December. Half of them — or enough for 12.5 million people — are earmarked for the U.S.

Shipments are set to begin to states within 24 hours of FDA clearance. And this week, a different panel of U.S. experts, established by the Centers for Disease Control and Prevention, will meet to decide how those initial supplies will be given out. They’re expected to reserve scarce first doses for health care workers and, if the shots work well enough in the frail elderly, for residents of long-term care facilities.

As more vaccine gradually becomes available in coming months, other essential workers and people at highest risk from the coronavirus would get in line. But enough for the general U.S. population isn’t expected until at least spring.

Outside the U.S., Zaks said significant supplies from Moderna would be available later, “in the first quarter” of next year.

“Obviously we are doing everything in our power to increase the capacity and accelerate the timelines,” he said.

Britain’s government said Sunday it has ordered 7 million doses from Moderna.

The U.K. also has ordered 40 million doses of the Pfizer-BioNTech vaccine, although it’s not clear how much of the companies’ limited December supply could go toward that order — if British health authorities clear the shots. Still, British hospitals are gearing up to receive some doses as early as next week.

Both Moderna’s and Pfizer’s vaccines are made with the same technology, using a piece of genetic code for the “spike” protein that studs the virus. That messenger RNA, or mRNA, instructs the body to make some harmless spike protein, training immune cells to recognize it if the real virus eventually comes along.

AstraZeneca Confusion

AstraZeneca and Oxford University last week announced confusing early results of their vaccine candidate from research in Britain and Brazil.

That vaccine appears 62% effective when tested as originally intended, with recipients given two full doses. But because of a manufacturing error, a small number of volunteers got a lower first dose — and AstraZeneca said in that group, the vaccine appeared to be 90% effective.

Experts say it’s unclear why the lower-dose approach would work better and that it may just be a statistical quirk.

A larger U.S. study of the AstraZeneca candidate still is underway that should eventually give the FDA a better picture of how well it works. The FDA has said any COVID-19 vaccine would have to be at least 50% effective.

Meanwhile Britain’s government will have to decide whether its U.K. data is sufficient for an early rollout there.

Still in the Pipeline

Johnson & Johnson also is in final-stage testing in the U.S. and several other countries to see if its vaccine candidate could work with just one dose.

Both the J&J and AstraZeneca vaccines work by using harmless cold viruses to carry the spike protein gene into the body and prime the immune system.

The different technologies have ramifications for how easily different vaccines could be distributed globally. The AstraZeneca shots won’t require freezer storage like the Pfizer and Moderna vaccines.

Candidates made with still other technologies are in late-stage testing, too. Another U.S. company, Novavax Inc., announced Monday that it has finished enrolling 15,000 people in a late-stage study in Britain and plans to begin recruiting even more volunteers for final testing in the U.S. and Mexico “in the coming weeks.”

Vaccines made by three Chinese companies and a Russian candidate also are being tested in thousands of people in countries around the world.

RELATED TOPICS:

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

Poll: Katie Porter Holds Early Edge in California Governor’s Race

DON'T MISS

Fresno Restaurateur Bobby Salazar Charged by Feds With Arson

DON'T MISS

Just 38% of Americans Support Trump’s Use of Troops to Police DC, Reuters/Ipsos Poll Finds

DON'T MISS

US to Seek Death Penalty in Washington D.C. Homicide Cases, Trump Says

DON'T MISS

ICE Is Suddenly Showing Up in CA Hospitals. Workers Want More Guidance on What to Do

DON'T MISS

Coarsegold Elementary Briefly Locked Down After Student Brings Starter Pistol

DON'T MISS

HHS Asks 46 States and Territories to Remove ‘Gender Ideology’ Content From Sex Ed Materials

DON'T MISS

Taylor Swift, Travis Kelce Announce Engagement

DON'T MISS

Valley Crime Stoppers’ Most Wanted Person of the Day: Enrique Arellano Ochoa

DON'T MISS

Wilted Lettuce. Rotten Strawberries. Here’s What Happens When You Round Up Farmworkers.

UP NEXT

Just 38% of Americans Support Trump’s Use of Troops to Police DC, Reuters/Ipsos Poll Finds

UP NEXT

US to Seek Death Penalty in Washington D.C. Homicide Cases, Trump Says

UP NEXT

Coarsegold Elementary Briefly Locked Down After Student Brings Starter Pistol

UP NEXT

HHS Asks 46 States and Territories to Remove ‘Gender Ideology’ Content From Sex Ed Materials

UP NEXT

Trump Urges Cracker Barrel to Revert to Old Logo

UP NEXT

California Farming Couple Seeks $300 Million for Aspen Estate

UP NEXT

Trump Administration Cannot Sue Maryland Federal Judges Over Immigration Order, Judge Rules

UP NEXT

US Threatens to Withhold Funding From States Over Truck Driver English Proficiency Rules

UP NEXT

Trump Takes His Fed Fight to Unprecedented Level With Effort to Fire Cook

UP NEXT

Trump Media, Crypto.com Announce Deal to Form Crypto Treasury Firm

US to Seek Death Penalty in Washington D.C. Homicide Cases, Trump Says

2 hours ago

ICE Is Suddenly Showing Up in CA Hospitals. Workers Want More Guidance on What to Do

2 hours ago

Coarsegold Elementary Briefly Locked Down After Student Brings Starter Pistol

2 hours ago

HHS Asks 46 States and Territories to Remove ‘Gender Ideology’ Content From Sex Ed Materials

3 hours ago

Taylor Swift, Travis Kelce Announce Engagement

3 hours ago

Valley Crime Stoppers’ Most Wanted Person of the Day: Enrique Arellano Ochoa

3 hours ago

Wilted Lettuce. Rotten Strawberries. Here’s What Happens When You Round Up Farmworkers.

3 hours ago

Big Tower District Name to Reopen Sequoia Brewing Co. in Fresno

4 hours ago

Families Leave Gaza City After Night of Bombardment, Israelis Protest

4 hours ago

Noble Credit Union Teams With Bulldog Foundation to Provide Full-Ride Scholarships

4 hours ago

Poll: Katie Porter Holds Early Edge in California Governor’s Race

With Gov. Gavin Newsom termed out and high-profile Democrats Kamala Harris and Lt. Gov. Eleni Kounalakis not running, California’s 2026 gove...

37 minutes ago

Katie Porter speaking at the CADEM Endorsing Convention General Session Senate Candidate Interviews Saturday afternoon.
37 minutes ago

Poll: Katie Porter Holds Early Edge in California Governor’s Race

bobby salazar
1 hour ago

Fresno Restaurateur Bobby Salazar Charged by Feds With Arson

Members of the National Guard walk at the National Mall after U.S. President Donald Trump deployed National Guard troops and ordered an increased presence of federal law enforcement to assist in crime prevention, in Washington, D.C., U.S., August 21, 2025. (Reuters File)
2 hours ago

Just 38% of Americans Support Trump’s Use of Troops to Police DC, Reuters/Ipsos Poll Finds

President Donald Trump holds a cabinet meeting at the White House in Washington, D.C., U.S., August 26, 2025. (Reuters File)
2 hours ago

US to Seek Death Penalty in Washington D.C. Homicide Cases, Trump Says

A view of a sign for the Dignity Health Glendale Memorial Hospital.
2 hours ago

ICE Is Suddenly Showing Up in CA Hospitals. Workers Want More Guidance on What to Do

A student at Coarsegold Elementary accidentally brought an unloaded starter pistol to school Monday, August 26, 2025, prompting a brief lockdown that has since been lifted, authorities said. (Madera County SO)
2 hours ago

Coarsegold Elementary Briefly Locked Down After Student Brings Starter Pistol

A person walks outside of the U.S. Department of Health and Human Services building after it was reported that the HHS will cut about 10,000 full-time jobs and close half of its regional offices, a major overhaul of the department under Health Secretary Robert F. Kennedy Jr., in Washington, D.C., U.S., March 27, 2025. (Reuters File)
3 hours ago

HHS Asks 46 States and Territories to Remove ‘Gender Ideology’ Content From Sex Ed Materials

Singer Taylor Swift and Kansas City Chiefs' Travis Kelce are seen during the final match between Italy's Jannik Sinner and Taylor Fritz of the U.S. (Reuters File)
3 hours ago

Taylor Swift, Travis Kelce Announce Engagement

Search

Help continue the work that gets you the news that matters most.

Send this to a friend